P A Canney1, M A Machin, J Curto. 1. Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK. peter.canney@northglasgow.scot.nhs.uk
Abstract
BACKGROUND: This was a feasibility study of the combination of Exemestane and the cyclooxygenase-2 (COX-2) inhibitor Celecoxib in advanced breast cancer. PATIENTS AND METHODS: Post-menopausal women with histologically proven, hormone receptor positive, advanced breast cancer who had progressive disease, normal blood counts, liver and renal function were eligible. Exemestane was given at a dose of 25 mg daily and Celecoxib at a dose of 400 mg bd. Responses were assessed according to RECIST criteria and toxicity was accessed according to CTC. The primary end-point was the percentage of patients who had neither discontinued therapy nor progressed at 6 months ('treatment successes'). RESULTS: Fifty-three eligible patients were enrolled. Of 30 patients with target lesions, 4 (13%) had a complete response (CR), 12 (40%) a partial response (PR) and 5 (17%) stable disease (SD). The best response in 18 of the 23 patients with no target lesions at baseline was stable disease. The clinical benefit (CR, PR+SD) for the whole group was therefore 39/53 (74%). The 'treatment success' rate was 60%. There were two non-malignant deaths which may have been associated with treatment. CONCLUSION: The combination of Exemestane and Celecoxib shows promising activity and tolerability and these results support the use of this combination in phase III clinical trials of short duration treatments.
BACKGROUND: This was a feasibility study of the combination of Exemestane and the cyclooxygenase-2 (COX-2) inhibitor Celecoxib in advanced breast cancer. PATIENTS AND METHODS: Post-menopausal women with histologically proven, hormone receptor positive, advanced breast cancer who had progressive disease, normal blood counts, liver and renal function were eligible. Exemestane was given at a dose of 25 mg daily and Celecoxib at a dose of 400 mg bd. Responses were assessed according to RECIST criteria and toxicity was accessed according to CTC. The primary end-point was the percentage of patients who had neither discontinued therapy nor progressed at 6 months ('treatment successes'). RESULTS: Fifty-three eligible patients were enrolled. Of 30 patients with target lesions, 4 (13%) had a complete response (CR), 12 (40%) a partial response (PR) and 5 (17%) stable disease (SD). The best response in 18 of the 23 patients with no target lesions at baseline was stable disease. The clinical benefit (CR, PR+SD) for the whole group was therefore 39/53 (74%). The 'treatment success' rate was 60%. There were two non-malignant deaths which may have been associated with treatment. CONCLUSION: The combination of Exemestane and Celecoxib shows promising activity and tolerability and these results support the use of this combination in phase III clinical trials of short duration treatments.
Authors: Maryam B Lustberg; Stephen P Povoski; Weiqiang Zhao; Rebecca M Ziegler; Yasuro Sugimoto; Amy S Ruppert; Amy M Lehman; Donna R Shiels; Ewa Mrozek; Bhuvaneswari Ramaswamy; Rachel M Layman; Robert W Brueggemeier; Charles L Shapiro Journal: Clin Breast Cancer Date: 2011-05-19 Impact factor: 3.225
Authors: Sharon A Glynn; Robyn L Prueitt; Lisa A Ridnour; Brenda J Boersma; Tiffany M Dorsey; David A Wink; Julie E Goodman; Harris G Yfantis; Dong H Lee; Stefan Ambs Journal: BMC Cancer Date: 2010-11-15 Impact factor: 4.430
Authors: Klaus H Baumann; Elmar Klusmeier; Isabel Eggemann; Silke Reinartz; Achim Almeroth; Mathias Kalder; Uwe Wagner Journal: Breast Cancer (Auckl) Date: 2009-04-07
Authors: B Liu; J K Wen; B H Li; X M Fang; J J Wang; Y P Zhang; C J Shi; D Q Zhang; M Han Journal: Cell Death Dis Date: 2011-07-28 Impact factor: 8.469